{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:23:02Z","timestamp":1787998982018,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Giant cell arteritis (GCA) is a vasculitis of large and medium-sized vessels that causes severe ophthalmic complications. Timely diagnosis and disease monitoring may prevent permanent vision loss but biomarkers for early ocular involvement are scarce. This study evaluates early optical coherence tomography (OCT) and OCT angiography (OCTA) biomarkers of ocular involvement in newly diagnosed GCA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Newly diagnosed GCA patients and similarly aged controls were enrolled. Participants underwent ocular examination, including OCT and OCTA imaging of the macula and optic disc. OCT metrics included macular ganglion cell layer (GCL) and peripapillary retinal nerve fiber layer (pRNFL) thickness. OCTA parameters included vessel density (VD), vessel skeleton density, and vessel diameter index (VDI). Associations between imaging biomarkers and GCA symptoms (ordinal GCA symptom score) were analyzed using age-adjusted regression models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We recruited 23 newly diagnosed GCA patients and 27 controls. VD and VDI in the deep retinal capillaries were significantly higher in GCA compared to controls (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.027). In patients reporting ocular symptoms, GCL thickness, volume and pRNFL thickness were increased in 11%, 22% and 17% of Early Treatment Diabetic Retinopathy Study subfields compared to controls (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.04). Additionally, GCL and pRNFL thicknesses were associated with GCA symptoms (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.041).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>OCT and OCTA imaging revealed structural and perfusion alterations in newly diagnosed GCA patients. Retinal microcirculation was altered, even regardless of the presence of ophthalmic symptoms. Structural changes correlated with systemic manifestations of GCA, suggesting a link between extracranial and intracranial involvement. Our findings underscore the potential diagnostic value of OCT and OCTA biomarkers for ocular involvement in GCA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12886-025-03997-x","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T22:01:50Z","timestamp":1744581710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Biomarkers of ocular manifestation in newly diagnosed giant cell arteritis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jan Henrik","family":"Terheyden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon M.","family":"Petzinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara C.","family":"Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"von der Emde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Behning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jungblut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Reinking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian W. M.","family":"Wintergerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin S.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"3997_CR1","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: A systematic review. JAMA. 2016;315:2442\u201358. https:\/\/doi.org\/10.1001\/jama.2016.5444.","journal-title":"JAMA"},{"key":"3997_CR2","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC201611010","volume":"165","author":"GS Hoffman","year":"2016","unstructured":"Hoffman GS. Giant cell arteritis. Ann Intern Med. 2016;165:ITC65\u201380. https:\/\/doi.org\/10.7326\/AITC201611010.","journal-title":"Ann Intern Med"},{"key":"3997_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.21075","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53:293\u20137. https:\/\/doi.org\/10.1002\/art.21075.","journal-title":"Arthritis Rheum"},{"key":"3997_CR4","first-page":"S","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil P, Williams M, Maw WW, Achilleos K, Elsideeg S, Dejaco C, et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33:S\u2013103.","journal-title":"Clin Exp Rheumatol"},{"key":"3997_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","volume":"112","author":"H Danesh-Meyer","year":"2005","unstructured":"Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112:1098\u2013103. https:\/\/doi.org\/10.1016\/j.ophtha.2005.01.036.","journal-title":"Ophthalmology"},{"key":"3997_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/s0161-6420(94)31102-x","volume":"101","author":"GT Liu","year":"1994","unstructured":"Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology. 1994;101:1779\u201385. https:\/\/doi.org\/10.1016\/s0161-6420(94)31102-x.","journal-title":"Ophthalmology"},{"key":"3997_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s0002-9394(99)80192-5","volume":"125","author":"SS Hayreh","year":"1998","unstructured":"Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125:509\u201320. https:\/\/doi.org\/10.1016\/s0002-9394(99)80192-5.","journal-title":"Am J Ophthalmol"},{"key":"3997_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00393-024-01565-0","volume":"83","author":"VS Sch\u00e4fer","year":"2024","unstructured":"Sch\u00e4fer VS, Petzinna SM, Schmidt WA. Neues in der bildgebung von Gro\u00dfgef\u00e4\u00dfvaskulitiden. [News on the imaging of large vessel vasculitis]. Z Rheumatol. 2024;83:800\u201311. https:\/\/doi.org\/10.1007\/s00393-024-01565-0.","journal-title":"Z Rheumatol"},{"key":"3997_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","volume":"13","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017;13:578\u201392. https:\/\/doi.org\/10.1038\/nrrheum.2017.142.","journal-title":"Nat Rev Rheumatol"},{"key":"3997_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford). 2016;55:66\u201370. https:\/\/doi.org\/10.1093\/rheumatology\/kev289.","journal-title":"Rheumatology (Oxford)"},{"key":"3997_CR11","doi-asserted-by":"publisher","first-page":"589794","DOI":"10.3389\/fmed.2020.589794","volume":"7","author":"S Monti","year":"2020","unstructured":"Monti S, Bartoletti A, Bellis E, Delvino P, Montecucco C. Fast-Track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse. Front Med (Lausanne). 2020;7:589794. https:\/\/doi.org\/10.3389\/fmed.2020.589794.","journal-title":"Front Med (Lausanne)"},{"key":"3997_CR12","doi-asserted-by":"publisher","first-page":"ii22","DOI":"10.1093\/rheumatology\/kex461","volume":"57","author":"WA Schmidt","year":"2018","unstructured":"Schmidt WA. Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology (Oxford). 2018;57:ii22\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/kex461.","journal-title":"Rheumatology (Oxford)"},{"key":"3997_CR13","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1093\/rheumatology\/keae287","volume":"63","author":"SM Petzinna","year":"2024","unstructured":"Petzinna SM, Burg LC, Bauer C-J, Karakostas P, Terheyden JH, Behning C, et al. Transorbital ultrasound in the diagnosis of giant cell arteritis. Rheumatology (Oxford). 2024;63:2379\u201386. https:\/\/doi.org\/10.1093\/rheumatology\/keae287.","journal-title":"Rheumatology (Oxford)"},{"key":"3997_CR14","doi-asserted-by":"crossref","unstructured":"Aumann S, Donner S, Fischer J, M\u00fcller F. High resolution imaging in microscopy and ophthalmology: new frontiers in biomedical optics: optical coherence tomography (OCT): principle and technical realization. Cham (CH); 2019.","DOI":"10.1007\/978-3-030-16638-0_3"},{"key":"3997_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/01658107.2022.2113901","volume":"46","author":"ON Klefter","year":"2022","unstructured":"Klefter ON, Hansen MS, Willerslev A, Faber C, Terslev L, Jensen MR, et al. Optical coherence tomography of peripapillary vessels in giant cell arteritis and ischaemic ocular disease. Neuroophthalmology. 2022;46:383\u20139. https:\/\/doi.org\/10.1080\/01658107.2022.2113901.","journal-title":"Neuroophthalmology"},{"key":"3997_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1136\/bjophthalmol-2017-310718","volume":"102","author":"ED Gaier","year":"2018","unstructured":"Gaier ED, Gilbert AL, Cestari DM, Miller JB. Optical coherence tomographic angiography identifies peripapillary microvascular dilation and focal non-perfusion in giant cell arteritis. Br J Ophthalmol. 2018;102:1141\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310718.","journal-title":"Br J Ophthalmol"},{"key":"3997_CR17","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1136\/ard-2022-223480","volume":"81","author":"C Ponte","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 American college of rheumatology\/eular classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81:1647\u201353. https:\/\/doi.org\/10.1136\/ard-2022-223480.","journal-title":"Ann Rheum Dis"},{"key":"3997_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.semarthrit.2021.04.014","volume":"51","author":"VS Sch\u00e4fer","year":"2021","unstructured":"Sch\u00e4fer VS, Chrysidis S, Schmidt WA, Duftner C, Iagnocco A, Bruyn GA, et al. OMERACT definition and reliability assessment of chronic ultrasound lesions of the axillary artery in giant cell arteritis. Semin Arthritis Rheum. 2021;51:951\u20136. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.04.014.","journal-title":"Semin Arthritis Rheum"},{"key":"3997_CR19","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/rheumatology\/kex289","volume":"56","author":"VS Sch\u00e4fer","year":"2017","unstructured":"Sch\u00e4fer VS, Juche A, Ramiro S, Krause A, Schmidt WA. Ultrasound cut-off values for intima-media thickness of Temporal, facial and axillary arteries in giant cell arteritis. Rheumatology (Oxford). 2017;56:1632. https:\/\/doi.org\/10.1093\/rheumatology\/kex289.","journal-title":"Rheumatology (Oxford)"},{"key":"3997_CR20","doi-asserted-by":"publisher","first-page":"e0230260","DOI":"10.1371\/journal.pone.0230260","volume":"15","author":"JH Terheyden","year":"2020","unstructured":"Terheyden JH, Wintergerst MWM, Falahat P, Berger M, Holz FG, Finger RP. Automated thresholding algorithms outperform manual thresholding in macular optical coherence tomography angiography image analysis. PLoS ONE. 2020;15:e0230260. https:\/\/doi.org\/10.1371\/journal.pone.0230260.","journal-title":"PLoS ONE"},{"key":"3997_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","volume":"9","author":"N Otsu","year":"1979","unstructured":"Otsu N. A threshold selection method from Gray-Level histograms. IEEE Trans Syst Man Cybern. 1979;9:62\u20136. https:\/\/doi.org\/10.1109\/TSMC.1979.4310076.","journal-title":"IEEE Trans Syst Man Cybern"},{"key":"3997_CR22","doi-asserted-by":"publisher","first-page":"OCT362","DOI":"10.1167\/iovs.15-18904","volume":"57","author":"AY Kim","year":"2016","unstructured":"Kim AY, Chu Z, Shahidzadeh A, Wang RK, Puliafito CA, Kashani AH. Quantifying microvascular density and morphology in diabetic retinopathy using Spectral-Domain optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57:OCT362\u201370. https:\/\/doi.org\/10.1167\/iovs.15-18904.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3997_CR23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.21037\/qims.2018.08.10","volume":"8","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Shi Y, Zhou H, Gregori G, Chu Z, Zheng F, et al. Accurate Estimation of choriocapillaris flow deficits beyond normal intercapillary spacing with swept source OCT angiography. Quant Imaging Med Surg. 2018;8:658\u201366. https:\/\/doi.org\/10.21037\/qims.2018.08.10.","journal-title":"Quant Imaging Med Surg"},{"key":"3997_CR24","doi-asserted-by":"publisher","first-page":"1408821","DOI":"10.3389\/fmed.2024.1408821","volume":"11","author":"L Vannozzi","year":"2024","unstructured":"Vannozzi L, Nicolosi C, Vicini G, Bacherini D, Giattini D, Urban ML, et al. Optical coherence tomography angiography findings in patients affected by giant cell arteritis, with and without ocular involvement: a pilot study. Front Med (Lausanne). 2024;11:1408821. https:\/\/doi.org\/10.3389\/fmed.2024.1408821.","journal-title":"Front Med (Lausanne)"},{"key":"3997_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1113\/jphysiol.1902.sp000911","volume":"28","author":"WM Bayliss","year":"1902","unstructured":"Bayliss WM. On the local reactions of the arterial wall to changes in internal pressure. J Physiol. 1902;28:220\u201331.","journal-title":"J Physiol"},{"key":"3997_CR26","unstructured":"Mendoza-Santiesteban CE, Patel N, Monaco C, Hedges TR. Distinctive pattern of ganglion cell layer loss in early ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2014:3391."},{"key":"3997_CR27","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1056\/NEJMra1413352","volume":"372","author":"V Biousse","year":"2015","unstructured":"Biousse V, Newman NJ. Ischemic optic neuropathies. N Engl J Med. 2015;372:2428\u201336. https:\/\/doi.org\/10.1056\/NEJMra1413352.","journal-title":"N Engl J Med"},{"key":"3997_CR28","doi-asserted-by":"publisher","first-page":"885463","DOI":"10.3389\/fmed.2022.885463","volume":"9","author":"Q Chen","year":"2022","unstructured":"Chen Q, Chen W, Feng C, Gong D, Zhang J, Bi Y, et al. Giant cell arteritis presenting with ocular symptoms: clinical characteristics and multimodal imaging in a Chinese case series. Front Med (Lausanne). 2022;9:885463. https:\/\/doi.org\/10.3389\/fmed.2022.885463.","journal-title":"Front Med (Lausanne)"},{"key":"3997_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3899\/jrheum.140188","volume":"42","author":"AG Singh","year":"2015","unstructured":"Singh AG, Kermani TA, Crowson CS, Weyand CM, Matteson EL, Warrington KJ. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42:309\u201315. https:\/\/doi.org\/10.3899\/jrheum.140188.","journal-title":"J Rheumatol"},{"key":"3997_CR30","doi-asserted-by":"crossref","unstructured":"Petzinna SM, Terheyden JH, Burg LC, Bauer C-J, Karakostas P, Behning C et al. Imaging of ophthalmic manifestations: optical coherence tomography angiography and transorbital ultrasound in giant cell arteritis. Rheumatol Int. 2025.","DOI":"10.1007\/s00296-025-05800-y"},{"key":"3997_CR31","doi-asserted-by":"publisher","first-page":"ii63","DOI":"10.1093\/rheumatology\/kex428","volume":"57","author":"I Vodopivec","year":"2018","unstructured":"Vodopivec I, Rizzo JF. Ophthalmic manifestations of giant cell arteritis. Rheumatology (Oxford). 2018;57:ii63\u201372. https:\/\/doi.org\/10.1093\/rheumatology\/kex428.","journal-title":"Rheumatology (Oxford)"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-03997-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-03997-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-03997-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T22:01:52Z","timestamp":1744581712000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-03997-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3997"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-03997-x","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and received approval from the ethics committee of the University Hospital Bonn, Germany (reference number: 097\/18). Written informed consent was obtained from every patient prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JHT: Bayer (Consulting, Funding, Honoraria); Novartis (Recipient, Honoraria), Roche (Funding), Okko (Consulting)SMP, LCB, VSS noneJJ: NoneKR: NoneFGH: Acucela (Consulting, Funding), Allergan (Funding), Apellis (Consulting, Funding), Bayer (Consulting, Funding), Boehringer-Ingelheim (Consulting), Bioeq\/ Formycon (F,C), CenterVue (Funding), Ellex (Funding), Roche\/Genentech (Consulting, Funding), Geuder (Consulting, Funding), Graybug (Consulting), Gyroscope (Consulting), Heidelberg Engineering (Consulting, Funding), IvericBio (Consulting, Funding), Kanghong (Consulting, Funding), LinBioscience (Consulting), NightStarX (Funding), Novartis (Consulting, Funding), Optos (Funding), Oxurion (Consulting), Pixium Vision (Consulting, Funding), Oxurion (Consulting), Stealth BioTherapeutics (Consulting), Zeiss (Funding, Consulting)TA: Novartis (Speaker honorarium), Astellas (Speaker honorarium, Advisory board), Apellis (Speaker honorarium), Heidelberg Engineering (Speaker honorarium), Bayer (Speaker honorarium), Roche (Speaker honorarium, Travel reimbursement), Nidek (Research funding, speaker honorarium)MWMW: Baxter Healthcare Corporation: research grant, Bayer AG: honoraria, glaucare GmbH: consultant, owner , Novartis Pharma GmbH: honoraria, grant, DigiSight Technologies: travel grant, D-EYE Srl: imaging devices, Heine Optotechnik GmbH: research funding, imaging devices, travel reimbursements, consultant; Eyenuk, Inc: free trial analysis; ASKIN & CO GmbH: travel reimbursement, honoraria; Berlin-Chemie AG: grant, travel reimbursements; Imaging devices were provided by Heidelberg Engineering, Optos, Carl Zeiss Meditec, and CenterVueRPF: Bayer (Consultant), Ellex (Consultant), Novartis (Consultant), Novartis (Funding), Ophtea (Consultant), Alimera (Consultant), Santhera (Consultant), Roche\/Genentech (Consultant), ICare (formerly CentreVue) (Funding), Zeiss (Funding)","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}